Affimed GmbH products

Lighting the way with clinical results: we are creating success with monotherapies and combination therapies. AFM13, a first-in-class ICE (innate cell engager) molecule targeting patients with CD30-positive lymphomas,⁴ showed antitumor responses in a Phase 1/2 trial as a monotherapy in 15 patients with T-cell lymphomas and cutaneous involvement (44% ORR).⁵ When used in combination with allogeneic NK cells (pre-complexing of AFM13 + cbNK), early clinical data in heavily pre-treated patients with Hodgkin lymphoma show a reduction in tumor burden as well as favorable safety.

AFM24, an EGFR-directed ICE® (innate cell engager) molecule, represents a distinctive mechanism that engages innate immune cells by recruiting NK cells and macrophages to the site of the tumor for effective and efficient tumor-cell killing. Potential to treat various solid tumor types with a more acceptable safety profile while remaining immune to the challenge of resistance.